---
pagetitle: "ICI resistance"
format:
  revealjs:
    transition: fade
    theme: [default, catppuccin.scss]
    cap-location: bottom
    appearance:
      appearparents: true
bibliography: /home/martin/Documents/PhD/sws_gr/references.bib
revealjs-plugins:
  - appearance
  - fontawesome
---

## {#title data-menu-title="Title" background-image="img/macchiato-bg.png"}

[Primary Resistance Paradox: When Immune Checkpoint Inhibitors meet their match]{.title} [Martin Hong <br> SWS Research Grand Rounds <br> 29 May 2024]{.subtitle}

## Overview {data-autoappear=true}

* Background
* Prospective biomarkers
* Significance of Research

# Background

## Origins of immune checkpoints

::::{.columns}

:::{.column width="60%"}
![](./img/james_allison_crop.jpg){width="300" fig-align="left" .animate__fadeInUp data-delay="0"}
<figcaption style="opacity: 0; animation: fadeInUp 2s ease-in-out forwards; animation-delay: 1.5s;">James Allison - CTLA4</figcaption>
:::

:::{.column width="40%"}
![](./img/tasuku_honjo.jpg){width="300" fig-align="left" .animate__fadeInUp data-delay="3000"}
<figcaption style="opacity: 0; animation: fadeInUp 2s ease-in-out forwards; animation-delay: 4.5s;">Tasuku Honjo - PD-1</figcaption>
:::

::::

::: {.notes}
James Allison and Tasuku Honjo won the Nobel Prize in Physiology or Medicine in 2018 for their discovery of checkpoints.
:::

## Role of immune checkpoints 

::::{.columns}

:::{.column width="40%"}

:::{.fragment fragment-index=1 .fade-left}
* Maintain tolerance to self {{< fa arrow-right >}} preventing auto-immunity
:::

:::{.fragment fragment-index=2 .fade-left}
* Hanahan & Weinberg identified immune evasion as a hallmark of cancer
:::

:::{.fragment fragment-index=4 .fade-left}
* Immune checkpoints, such as CTLA4 and PD-1, inhibits activation of lymphocytes when there is binding to APCs
:::

:::

:::{.column width="60%"}

::: {.r-stack}
![](./img/h_w_2011.jpg){.fragment fragment-index=3 .fade-left width="600"} ^[@hanahanHallmarksCancerNext2011]

![](./img/t_act.png){.fragment fragment-index=5 .fade-left width="250"} ^[Created with BioRender.com]

![](./img/t_ctla4.png){.fragment fragment-index=6 .fade-left width="250"}

![](./img/t-pd1.png){.fragment fragment-index=7 .fade-left width="250"}
:::

:::

::::

## Immune checkpoint inhibitors (ICIs) 

::::{.columns}

:::{.column width="40%"}

:::{.fragment .fade-left}
* Monoclonal antibodies against:
  + CTLA4
  + PD-1
  + PD-L1
:::

:::{.fragment .fade-left}
:::{.fragment .semi-fade-out}
* Inhibitory signal
:::
:::

:::{.fragment .fade-left}
* Resulting in immune activation & ðŸ¤ž restoration of immune recognition of cancer
:::

:::

:::{.column width="60%"}

:::{.fragment .fade-left}
* Some ICIs include:
  + Ipilimumab (anti-CTLA4)
  + Pembrolizumab (anti-PD-1)
  + Nivolumab (anti-PD-1)
  + Durvalumab (anti-PD-L1)
  + Atezolizumab (anti-PD-L1)
:::

:::

::::

# What is currently known

## Markers to predict response

::::{.columns}

:::{.column width="50%"}

:::{.fragment fragment-index=1 .fade-left}
* PD-L1 expression
:::

</br>

:::{.fragment fragment-index=3 .fade-left}
* Tumour mutational burden 
:::

</br></br>

:::{.fragment fragment-index=5 .fade-left}
* DNA mismatch repair deficiency/High microsatellite instability
:::

:::

:::{.column width="50%"}

:::{.fragment fragment-index=2 .fade-right}
* So far only useful in some tumours, and variable testing (tumour only, TME as well)
:::

:::{.fragment fragment-index=4 .fade-right}
* Looking most useful, but unable to test routinely in clinical practice
:::

</br>

:::{.fragment fragment-index=6 .fade-right}
* An indirect way to assess for TMB, but so far not fully useful in all tumour types
:::

:::

::::

# Why look for biomarkers for resistance if there is already biomarkers to predict response?

---

![](./img/kn042_tps50.png){.animate__bounceInRight .animate__slow} ^[@decastroFiveYearOutcomesPembrolizumab2023]

::: {.notes}
This is the overall survival for KN042, which is one of the main IO vs chemo trials in lung cancer. Note despite picking for TPS >= 50%, there is still a greater proportion of people dying in the pembrolizumab group in the first 6-ish months then those who had chemotherapy 
:::

# What is known so far

## STK11/LKB1 

::::{.columns}

:::{.column width="40%"}

:::{.fragment fragment-index=1 .fade-left}
* STK11/LKB1 is a serine/threonine kinase involved in:
:::

:::{.fragment fragment-index=2 .fade-left}
  + Cellular energy signalling - particularly in stressful situations
:::

:::{.fragment fragment-index=3 .fade-left}
  + Tumour suppressor - affects the mTOR pathway
:::

:::{.fragment fragment-index=4 .fade-left}
* LKB1 germline mutation is most famous as the cause of Peutz-Jeghers syndrome 
:::

:::

:::{.column width="60%"}

:::{.fragment fragment-index=5 .fade-right}
+--------------------------------------------------------------------------------------------------------------+
| **Diagnostic criteria**                                                                                      |
+--------------------------------------------------------------------------------------------------------------+
| 2 or more histologically confirmed Peutz-Jeghers (PJ) polyps                                                 |
+--------------------------------------------------------------------------------------------------------------+
| Any number of PJ polyps in a person with a known family history of PJS in a close relative                   |
+--------------------------------------------------------------------------------------------------------------+
| Characteristic mucocutaneous pigmentation in an individual who has a family history of PJS in close relative |
+--------------------------------------------------------------------------------------------------------------+
| Any number of PJ polyps in an individual with the characteristic mucocutaneous pigmentation                  |
+--------------------------------------------------------------------------------------------------------------+
:::

:::

::::

## STK11/LKB1 in lung cancer

:::{.fragment fragment-index=1 .fade-left}
* STK11/LKB1 mutations are found in 30% of lung cancers
:::

:::{.fragment fragment-index=2 .fade-left}
* STK11/LKB1 loss has been associated with:
  + Higher grade, LN metastases and poorer OS in breast cancer
  + Promotes metastases in melanoma tumour models
:::

:::{.fragment fragment-index=3 .fade-left}
* STK11 has been found to be commonly co-mutated with KRAS mutations in lung cancer
:::

:::{.fragment fragment-index=4 .fade-left}
* In lung cancer samples and *in vivo* studies, STK11 loss {{< fa arrow-right >}} lower tumour infiltration of lymphocytes
:::

## STING

::::{.columns}

:::{.column width="50%"}

:::{.fragment fragment-index=1 .fade-left}
* cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is an important immune pathway in cells
:::

:::{.fragment fragment-index=3 .fade-left}
* The pathway leads to formation of pro-inflammatory cytokines after detecting cytosolic DNA
:::

:::{.fragment fragment-index=4 .fade-left}
* This is important in dealing with viral infections, but also in tumours, DNA damage {{< fa arrow-right >}} cytosolic DNA
:::

:::

:::{.column width="50%"}

:::{.fragment fragment-index=2 .fade-left fig-align="right"}

![](./img/sting_pathway.png)^[Created with BioRender.com]

:::

:::

::::

## STK11 & STING 

![](./img/stk11_sting.png){.absolute width="350" top=100 left=400 .animate__fadeOut .animate__slow data-delay="30000"}^[Created with BioRender.com]

![](./img/stk11loss_sting.png){.absolute width="350" top=100 left=400 .animate__fadeIn .animate__slow data-delay="500"}

:::{.notes}
This is the presumed interaction between STK11/AMPK pathway and cGAS-STING pathways. The reduction in STK11 leads to reduction in AMPK. This leads to both direct and indirect downregulation of STING expression by methylation of the STING promoter by:
1. EZH2
2. DNMT1
The indirect pathway is due to reduction in S-adenosyl-methionine which is a main source of methyl group for DNMT1.
:::

## STING haplotypes

:::{.fragment .fade-left}
* As explained previously, cGAS-STING pathway has an important role in immune activation
:::

::: {.fragment .fade-left}
* However, it is recognised that there are STING SNP variants in people with variable activity:
  + R71H, G230A, R293Q (most common variant)
  + R232H
:::

::: {.fragment .fade-left}
* The variants can lead to reduction in STING activity {{< fa arrow-right >}} reduced pro-inflammatory cytokines
  + This may have arisen as a protective mechanism in some populations against viral infections
:::

::: {.fragment .fade-left}
* However, does {{< fa arrow-down >}} activity {{< fa arrow-right >}} poor tumour immune response?
:::

## Other possible markers

:::{.fragment .fade-left}
* TCR repertoire (e.g. diversity)
:::

::: {.fragment .fade-left}
* Cytokine levels prior to starting treatment
:::

# Why is understanding primary resistance important?

## Neoadjuvant treatment
:::: {.columns}

::: {.column width="50%"}

::: {.fragment .fade-left}
* Neoadjuvant treatment = Cancer treatment prior to surgery
:::
::: {.fragment .fade-left}
* This can lead to:
  + Shrinkage of cancer {{< fa arrow-right >}} improved surgery
  + May be only opportunity to have systemic treatment
  + In some cancers, better survival
:::
::: {.fragment .fade-left}
* However, not all patients respond to treatment as discussed.
:::

:::

::: {.column width="50%"}

::: {.fragment .fade-right}
![](./img/kn671.png)^[@wakeleePerioperativePembrolizumabEarlyStage2023]
:::

:::

::::
## Aims of project

:::{.fragment .fade-left}
* Investigate the impact of the STING pathway in immunotherapy resistance
:::

::: {.fragment .fade-left}
* Investigate STING haplotypes and their possible role in immune suppressive TME
:::

::: {.fragment .fade-left}
* Investigate other possible factors which may impact on immune suppressive TME
:::

## Acknowledgements
* Supervisors: Prof Tara Roberts & Prof Wei Chua for all of their time and advice
* Dr Alex James and Dr Yafeng Ma for all of their input - particularly around STING haplotypes

## References

::: {#refs}
:::

# Any questions?
